Hepatocyte Toll-Like Receptor 5 Promotes Bacterial Clearance and Protects Mice Against High-Fat Diet–Induced Liver Disease

Cellular and Molecular Gastroenterology and Hepatology

Volumn 2, Issue 5, 2016, Pages 584-604

  Etienne Mesmin, Lucie ^a   Vijay Kumar, Matam ^b   Gewirtz, Andrew T ^a   Chassaing, Benoit ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Hepatocytes; Inflammation; Innate Immunity; Steatosis; TLR5

Indexed keywords

CARBON TETRACHLORIDE; CHOLINE; CONCANAVALIN A; CXCL1 CHEMOKINE; FLAGELLIN; INFLAMMASOME; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; METHIONINE; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR C4; TOLL LIKE RECEPTOR 5; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL CLEARANCE; CONTROLLED STUDY; DISEASE PREDISPOSITION; EXPERIMENTAL FATTY LIVER; FEMALE; LIPID DIET; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIBLING;

EID: 84979680188     PISSN: None     EISSN: 2352345X     Source Type: Journal    
DOI: 10.1016/j.jcmgh.2016.04.007     Document Type: Article

References (48)

1. 1 Hooper, L.V., Macpherson, A.J., Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat Rev Immunol 10 (2010), 159–169.
2. 2 Chassaing, B., Darfeuille-Michaud, A., The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. Gastroenterology 140 (2011), 1720–1728.
3. 3 Xavier, R.J., Podolsky, D.K., Unravelling the pathogenesis of inflammatory bowel disease. Nature 448 (2007), 427–434.
4. 4 Sartor, R.B., Microbial influences in inflammatory bowel diseases. Gastroenterology 134 (2008), 577–594.
5. 5 Cader, M.Z., Kaser, A., Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation. Gut 62 (2013), 1653–1664.
6. 6 Caricilli, A.M., Picardi, P.K., de Abreu, L.L., et al. Gut microbiota is a key modulator of insulin resistance in TLR 2 knockout mice. PLoS Biol, 9, 2011, e1001212.
7. 7 Henao-Mejia, J., Elinav, E., Jin, C., et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482 (2012), 179–185.
8. 8 Vijay-Kumar, M., Aitken, J.D., Carvalho, F.A., et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 328 (2010), 228–231.
9. 9 Chassaing, B., Koren, O., Carvalho, F.A., et al. AIEC pathobiont instigates chronic colitis in susceptible hosts by altering microbiota composition. Gut 63 (2014), 1069–1080.
10. 10 Ubeda, C., Lipuma, L., Gobourne, A., et al. Familial transmission rather than defective innate immunity shapes the distinct intestinal microbiota of TLR-deficient mice. J Exp Med 209 (2012), 1445–1456.
11. 11 Chassaing, B., Ley, R.E., Gewirtz, A.T., Intestinal epithelial cell toll-like receptor 5 regulates the intestinal microbiota to prevent low-grade inflammation and metabolic syndrome in mice. Gastroenterology 147 (2014), 1363–1377 e17.
12. 12 Balmer, M.L., Slack, E., de Gottardi, A., et al. The liver may act as a firewall mediating mutualism between the host and its gut commensal microbiota. Sci Transl Med, 6, 2014, 237ra66.
13. 13 Chassaing, B., Etienne-Mesmin, L., Gewirtz, A.T., Microbiota-liver axis in hepatic disease. Hepatology 59 (2014), 328–339.
14. 14 Cani, P.D., Amar, J., Iglesias, M.A., et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56 (2007), 1761–1772.
15. 15 Pierre, N., Deldicque, L., Barbe, C., et al. Toll-like receptor 4 knockout mice are protected against endoplasmic reticulum stress induced by a high-fat diet. PLoS One, 8, 2013, e65061.
16. 16 Huang, W., Metlakunta, A., Dedousis, N., et al. Depletion of liver Kupffer cells prevents the development of diet-induced hepatic steatosis and insulin resistance. Diabetes 59 (2010), 347–357.
17. 17 Carvalho, F.A., Aitken, J.D., Vijay-Kumar, M., et al. Toll-like receptor-gut microbiota interactions: perturb at your own risk!. Ann Rev Physiol 74 (2012), 177–198.
18. 18 Abreu, M.T., Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat Rev Immunol 10 (2010), 131–144.
19. 19 Uematsu, S., Jang, M.H., Chevrier, N., et al. Detection of pathogenic intestinal bacteria by Toll-like receptor 5 on intestinal CD11c+ lamina propria cells. Nat Immunol 7 (2006), 868–874.
20. 20 Vijay-Kumar, M., Carvalho, F.A., Aitken, J.D., et al. TLR5 or NLRC4 is necessary and sufficient for promotion of humoral immunity by flagellin. Eur J Immunol 40 (2010), 3528–3534.
21. 21 Sahai, A., Malladi, P., Melin-Aldana, H., et al. Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model. Am J Physiol Gastrointest Liver Physiol 287 (2004), G264–G273.
22. 22 Gewirtz, A.T., Navas, T.A., Lyons, S., et al. Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J Immunol 167 (2001), 1882–1885.
23. 23 Mohar, I., Brempelis, K.J., Murray, S.A., et al. Isolation of non-parenchymal cells from the mouse liver. Methods Mol Biol 1325 (2015), 3–17.
24. 24 Conrad, E., Resch, T.K., Gogesch, P., et al. Protection against RNA-induced liver damage by myeloid cells requires type I interferon and IL-1 receptor antagonist in mice. Hepatology 59 (2014), 1555–1563.
25. 25 Jiang, N., Zhang, X., Zheng, X., et al. A novel in vivo siRNA delivery system specifically targeting liver cells for protection of ConA-induced fulminant hepatitis. PLoS One, 7, 2012, e44138.
26. 26 Dorn, C., Heilmann, J., Hellerbrand, C., Protective effect of xanthohumol on toxin-induced liver inflammation and fibrosis. Int J Clin Exp Pathol 5 (2012), 29–36.
27. 27 Mehlem, A., Hagberg, C.E., Muhl, L., et al. Imaging of neutral lipids by oil red O for analyzing the metabolic status in health and disease. Nat Protoc 8 (2013), 1149–1154.
28. 28 Burdelya, L.G., Brackett, C.M., Kojouharov, B., et al. Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist. Proc Natl Acad Sci U S A 110 (2013), E1857–E1866.
29. 29 Wang, H.X., Liu, M., Weng, S.Y., et al. Immune mechanisms of concanavalin A model of autoimmune hepatitis. World J Gastroenterol 18 (2012), 119–125.
30. 30 Sinclair, E.M., Yusta, B., Streutker, C., et al. Glucagon receptor signaling is essential for control of murine hepatocyte survival. Gastroenterology 135 (2008), 2096–2106.
31. 31 Carvalho, F.A., Nalbantoglu, I., Ortega-Fernandez, S., et al. Interleukin-1beta (IL-1beta) promotes susceptibility of Toll-like receptor 5 (TLR5) deficient mice to colitis. Gut 61 (2012), 373–384.
32. 32 Vijay-Kumar, M., Sanders, C.J., Taylor, R.T., et al. Deletion of TLR5 results in spontaneous colitis in mice. J Clin Invest 117 (2007), 3909–3921.
33. 33 Tong, L., Acetyl-coenzyme A carboxylase: crucial metabolic enzyme and attractive target for drug discovery. Cell Mol Life Sci 62 (2005), 1784–1803.
34. 34 Le Roy, T., Llopis, M., Lepage, P., et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 62 (2013), 1787–1794.
35. 35 Musso, G., Gambino, R., Cassader, M., Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded?. Diabetes Care 33 (2010), 2277–2284.
36. 36 Cani, P.D., Bibiloni, R., Knauf, C., et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57 (2008), 1470–1481.
37. 37 Rivera, C.A., Adegboyega, P., van Rooijen, N., et al. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol 47 (2007), 571–579.
38. 38 Saberi, M., Woods, N.B., de Luca, C., et al. Hematopoietic cell-specific deletion of toll-like receptor 4 ameliorates hepatic and adipose tissue insulin resistance in high-fat-fed mice. Cell Metab 10 (2009), 419–429.
39. 39 Gieling, R.G., Wallace, K., Han, Y.P., Interleukin-1 participates in the progression from liver injury to fibrosis. Am J Physiol Gastrointest Liver Physiol 296 (2009), G1324–G1331.
40. 40 DeSantis, D.A., Ko, C.W., Liu, Y., et al. Alcohol-induced liver injury is modulated by Nlrp3 and Nlrc4 inflammasomes in mice. Mediators Inflamm, 2013, 2013, 751374.
41. 41 Szabo, G., Petrasek, J., Inflammasome activation and function in liver disease. Nat Rev Gastroenterol Hepatol 12 (2015), 387–400.
42. 42 Carvalho, F.A., Koren, O., Goodrich, J.K., et al. Transient inability to manage proteobacteria promotes chronic gut inflammation in TLR5-deficient mice. Cell Host Microbe 12 (2012), 139–152.
43. 43 Zeng, H., Wu, H., Sloane, V., et al. Flagellin/TLR5 responses in epithelia reveal intertwined activation of inflammatory and apoptotic pathways. Am J Physiol Gastrointest Liver Physiol 290 (2006), G96–G108.
44. 44 Salamone, G.V., Petracca, Y., Fuxman Bass, J.I., et al. Flagellin delays spontaneous human neutrophil apoptosis. Lab Invest 90 (2010), 1049–1059.
45. 45 Vijay-Kumar, M., Wu, H., Jones, R., et al. Flagellin suppresses epithelial apoptosis and limits disease during enteric infection. Am J Pathol 169 (2006), 1686–1700.
46. 46 Vijay-Kumar, M., Aitken, J.D., Sanders, C.J., et al. Flagellin treatment protects against chemicals, bacteria, viruses, and radiation. J Immunol 180 (2008), 8280–8285.
47. 47 Zhang, B., Chassaing, B., Shi, Z., et al. Viral infection. Prevention and cure of rotavirus infection via TLR5/NLRC4-mediated production of IL-22 and IL-18. Science 346 (2014), 861–865.
48. 48 Alazawi, W., Spyrou, A., Lahiri, R., et al. PMO-141 flagellin-induced IL-6 production is selectively impaired in patients with cirrhosis. Gut, 61, 2012, A130.